Multiparametric quantitative MRI could potentially help differentiate between Duchenne muscular dystrophy and Becker muscular dystrophy early and improve the management of these conditions.

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference – Company to host an Industry Forum to discuss ...

Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...

US-based biotechnology company Edgewise Therapeutics has reported positive two-year topline data from the ARCH clinical trial of sevasemten (EDG-5506) in adults with Becker muscular dystrophy.

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), with a group of more than 150 advocates, will head to Capitol Hill ...

Details of the Edgewise presentations at MDA: Edgewise Industry Forum Edgewise is sponsoring an Industry Forum, “Spotlight on Becker muscular dystrophy: Understanding the lived experience of ...

Edgewise is sponsoring an Industry Forum, "Spotlight on Becker muscular dystrophy: Understanding the lived experience of Becker and clinical advancements with a novel agent." Only conference ...

Title: P10: Prediction of North Star Ambulatory Assessment trajectories in Becker muscular dystrophy: Model development and validation Title: P11: Two-year sevasemten treatment outcomes in Becker ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an investigational orally ...